Japan Zolbetuximab Filing Heats Up CLDN18.2 Competition

US, EU, China Filings Also Expected

Astellas says its first approval filing globally for zolbetuximab - in Japan for gastric cancer - came faster than expected, as Scrip takes a look at the latest status of other CLDN18.2-targeting candidates in late clinical trials.

As Zolbetuximab reaches for approval, it awaits fierce competition for CLDN18.2-targeting drugs.
With first filing, zolbetuximab appears to be leading leading fierce global competition for CLDN18.2-targeting drugs. • Source: Shutterstock

The fierce competition globally around Claudin (CLDN) 18.2-targeting cancer drugs has entered the next phase with Astellas Pharma, Inc.'s first approval filing globally for its first-in-class antibody zolbetuximab, in Japan for CLDN 18.2-positive gastric cancer on 9 June.

Any successful approval, which may come within 12 months assuming standard review timelines in the country, could mark the pioneering...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category